Replies to post #662672 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Wrong board LC.

[The Danish Dude]

Ahh its pump and dump time again. The NVCR managements last stand.

AI says:

Given that the final data from Novocure's trial is expected in 2026, if the results are favorable and the company submits their application promptly, the FDA review process could start thereafter. The FDA review process can take anywhere from a few months to a couple of years, depending on the complexity of the data and the urgency of the medical need. Therefore, if all goes well, approval could potentially be expected a few years after the final trial data is available, possibly in the late 2020s.

Current: $15.32
52 week low: $10.87
52 week high: $103.69

Looking good. With a little look management can pump it a thursday again, sell friday and put out a "well things are not so good" PR on monday.

What differs trident novocure from novocures optune?

ChatGPT
The TRIDENT trial by Novocure is investigating the use of Optune Gio®, formerly known as Optune®, in a new treatment setting for glioblastoma (GBM). Optune is an established noninvasive cancer treatment that uses Tumor Treating Fields (TTFields) to disrupt cell division in cancer cells. It's typically used in combination with temozolomide after debulking surgery and the completion of radiation therapy in adults with newly diagnosed GBM.

The key difference with the TRIDENT trial is the timing of introducing Optune Gio® therapy. In this trial, Optune Gio® is being used concurrently with radiation therapy and temozolomide right from the start of treatment, rather than after the completion of radiation therapy as in the current standard practice. The trial aims to test whether initiating TTFields therapy earlier, at the same time as radiation therapy and temozolomide, can lead to more pronounced cytotoxic effects in glioma cell lines and potentially extend patient survival.

The TRIDENT study is a large-scale, randomized, open-label trial, enrolling 950 adult patients with newly diagnosed GBM. The approach in the TRIDENT trial represents a potential evolution in the treatment paradigm by introducing TTFields therapy earlier in the treatment journey of GBM patients.

The concept behind Optune, including Optune Gio®, is based on the unique mechanism of TTFields therapy, which uses electric fields to physically disrupt cell division, targeting dividing cancer cells while causing minimal damage to healthy cells. The most common side effect reported with TTFields therapy is mild to moderate skin irritation.

In summary, while Optune (now known as Optune Gio®) is an established treatment for GBM, the TRIDENT trial explores a new approach by introducing this therapy earlier in the treatment regimen, alongside radiation therapy and temozolomide, potentially improving treatment outcomes for GBM patients.